In after-hours trade Tuesday, Supernus Pharmaceuticals (SUPN) shares soared more than 24% percent to $27.99, following the firm revealed promising findings from a trial of its new treatment for attention deficit hyperactivity disorder, or ADHD. Supernus reported Tuesday afternoon that its intended goal was met in a phase 3 trial of the medication, known as SPN-812, in adults.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
The Food and Drug Administration is actively reviewing the drug for use in children aged 6 to 17, and once it is approved by the FDA, Supernus plans to ask that the drug be considered for adults as well.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Shares surged more than 40% as trades resumed after the end of after-hours trading Tuesday afternoon, but gradually declined to around 20 percentsurge by the end of the extended session.
Read More
